Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:AGEN

Agenus Q3 2026 Earnings Date & Estimates

Agenus logo
$6.16 -0.17 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.08 (+1.28%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agenus is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 7:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
7:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Agenus in Q3 2026

Agenus is expected to post earnings of $0.02 per share on revenue of $28.19 million. In the same quarter a year earlier Agenus reported $1.94 per share on revenue of $30.24 million. Agenus last reported on August 7, 2026, posting -$0.01 per share and missing the $0.05 consensus estimate. Agenus has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.02
Expected Revenue
$28.19 million
Prior-Year EPS
$1.94
Prior-Year Revenue
$30.24 million
Expected EPS Growth
-99.0%
Expected Revenue Growth
-6.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Missed by -$0.06)
Last Quarter Revenue
$34.52 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Agenus Q3 2026 Earnings FAQ

Agenus (NASDAQ:AGEN) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Agenus' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 7:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Agenus to post earnings of $0.02 per share for Q3 2026.

The consensus revenue estimate for Agenus is $28.19 million for Q3 2026.

Agenus Earnings Headlines

Biggest stock movers Monday: XCNR, SGRY, AGEN
October 26 at 5:50 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/biggest-stock-movers-monday-xcnr-sgry-agen/ar-AA2g4K4W
Agenus reports response rate in colon cancer trial
October 25 at 5:53 PM  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/agenus-reports-response-rate-in-colon-cancer-trial/ar-AA2g2SvI
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.tc pixel
October 26 at 1:00 AM  |  Profits Run (Ad)
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
October 25 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261025332881/en/agenus-reports-72-of-patients-with-locally-advanced-dmmr-colon-cancer-had-no-cancer-remaining-at-surgery-following-six-weeks-of-botbal-in-phase-2-neoasis-study-at-esmo-2026/
Chardan Capital Reaffirms Buy Rating for Agenus (NASDAQ:AGEN)
October 24 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151679
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
October 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agenus-third-quarter-2026-financial-203000728.html
See More Agenus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email.

About Agenus

Agenus (NASDAQ:AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011. Agenus is headquartered in Lexington, Massachusetts, and conducts research and development through its own operations and collaborations with biotechnology and pharmaceutical partners. Garo H. Armen, who founded the company, serves as its chairman and chief executive officer.

View Agenus Profile
Earnings Tools